DDMAC issues untitled letter concerning Ista journal ad

Share this article:
The FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) issued an untitled letter to Ista Pharmaceuticals concerning a journal advertisement for Vitrase (hyaluonidase injection), indicated for the treatment of vitreous hemorrhage and diabetic retinopathy.
In the letter, DDMAC said the journal ad is false or misleading because it fails to reveal material
facts, thus minimizing the risks associated with treatment with Vitrase. "DDMAC requests that Ista immediately cease the dissemination of violative promotional materials for Vitrase," the letter stated.
A spokesperson for Ista was not immediately available for comment.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...